John Overington
Chief Tech/Sci/R&D Officer at EXSCIENTIA PLC
Profile
Dr. John P.
Overington is a Chief Technology Officer at Exscientia Plc.
He is on the Board of Directors at The Cambridge Crystallographic Data Centre.
Dr. Overington was previously employed as a Senior Vice President-Drug Discovery by Galapagos Biotech Ltd., a Principal by Pfizer Inc., and a Chief Information Officer by Medicines Discovery Catapult Ltd.
He received his undergraduate degree from the University of Bath and a doctorate degree from Birkbeck University of London.
John Overington active positions
| Companies | Position | Start |
|---|---|---|
| EXSCIENTIA PLC | Chief Tech/Sci/R&D Officer | 01/05/2024 |
The Cambridge Crystallographic Data Centre
 The Cambridge Crystallographic Data Centre Data Processing ServicesTechnology Services The Cambridge Crystallographic Data Centre, founded in 1965, is a non-profit company that specializes in providing support and licensing for their CSD data and software. The company is based in Cambridge, UK and has subsidiaries in the United Kingdom. The British company's historical structures date back to the 1920s. The CS-Crossminer software allows users to build pharmacophore queries and mine the CS data simultaneously. | Director/Board Member | - |
Former positions of John Overington
| Companies | Position | End |
|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | - |
Medicines Discovery Catapult Ltd.
 Medicines Discovery Catapult Ltd. Miscellaneous Commercial ServicesCommercial Services Medicines Discovery Catapult Ltd. is a not-for-profit organization that enables the community to accelerate innovative drug discovery. The private company is based in Macclesfield, UK, and has subsidiaries in the United Kingdom. The British company focuses on pioneering the next generation of medicine discovery techniques and technologies by validating new ways of discovering medicines and driving key talent and expertise across the sector. The CEO of the company is Chris Molloy. | Chief Tech/Sci/R&D Officer | - |
Galapagos Biotech Ltd.
 Galapagos Biotech Ltd. BiotechnologyHealth Technology Galapagos Biotech Ltd. operates as a drug discovery company which provides discovery technologies and services. Its technologies include Chemogenomics and Silico. The company was founded by Kenneth Leslie Powell and Janet Maureen Thornton in July 8, 1997 and is headquartered in Cambridge, the United Kingdom. | Corporate Officer/Principal | - |
Training of John Overington
| University of Bath | Undergraduate Degree |
| Birkbeck University of London | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| EXSCIENTIA PLC | Health Technology |
| Private companies | 3 |
|---|---|
Galapagos Biotech Ltd.
Galapagos Biotech Ltd. BiotechnologyHealth Technology Galapagos Biotech Ltd. operates as a drug discovery company which provides discovery technologies and services. Its technologies include Chemogenomics and Silico. The company was founded by Kenneth Leslie Powell and Janet Maureen Thornton in July 8, 1997 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
The Cambridge Crystallographic Data Centre
The Cambridge Crystallographic Data Centre Data Processing ServicesTechnology Services The Cambridge Crystallographic Data Centre, founded in 1965, is a non-profit company that specializes in providing support and licensing for their CSD data and software. The company is based in Cambridge, UK and has subsidiaries in the United Kingdom. The British company's historical structures date back to the 1920s. The CS-Crossminer software allows users to build pharmacophore queries and mine the CS data simultaneously. | Technology Services |
Medicines Discovery Catapult Ltd.
Medicines Discovery Catapult Ltd. Miscellaneous Commercial ServicesCommercial Services Medicines Discovery Catapult Ltd. is a not-for-profit organization that enables the community to accelerate innovative drug discovery. The private company is based in Macclesfield, UK, and has subsidiaries in the United Kingdom. The British company focuses on pioneering the next generation of medicine discovery techniques and technologies by validating new ways of discovering medicines and driving key talent and expertise across the sector. The CEO of the company is Chris Molloy. | Commercial Services |
- Stock Market
- Insiders
- John Overington
